Advisors Asset Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Advisors Asset Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-56,626	Closed	-$136K	–	1653
2018 Q1	$136K	Sell	56,626 -16,398	-22%	-$44.8K	﹤0.01%	1286
2017 Q4	$200K	Sell	73,024 -43,940	-38%	-$135K	﹤0.01%	1250
2017 Q3	$397K	Sell	116,964 -49,669	-30%	-$138K	0.01%	1125
2017 Q2	$412K	Sell	166,633 -119,183	-42%	-$274K	0.01%	1144
2017 Q1	$649K	Sell	285,816 -24,098	-8%	-$53.3K	0.01%	1009
2016 Q4	$657K	Sell	309,914 -171,029	-36%	-$477K	0.01%	1012
2016 Q3	$1.61M	Sell	480,943 -874,299	-65%	-$2.78M	0.03%	696
2016 Q2	$4.25M	Sell	1,355,242 -1,006,812	-43%	-$3.36M	0.07%	406
2016 Q1	$7.87M	Sell	2,362,054 -1,044,916	-31%	-$3.26M	0.13%	230
2015 Q4	$12.1M	Sell	3,406,970 -1,169,198	-26%	-$4.89M	0.19%	134
2015 Q3	$23M	Sell	4,576,168 -796,945	-15%	-$4.57M	0.37%	45
2015 Q2	$34.5M	Buy	5,373,113 +76,665	+1%	+$514K	0.47%	28
2015 Q1	$37.3M	Buy	5,296,448 +296,719	+6%	+$2.15M	0.5%	30
2014 Q4	$38.5M	Buy	4,999,729 +153,944	+3%	+$1.22M	0.52%	27
2014 Q3	$36.2M	Buy	4,845,785 +118,420	+3%	+$1.1M	0.5%	35
2014 Q2	$45.8M	Buy	4,727,365 +1,051,880	+29%	+$9.38M	0.63%	20
2014 Q1	$30.5M	Buy	3,675,485 +332,847	+10%	+$2.85M	0.46%	42
2013 Q4	$28.2M	Buy	3,342,638 +280,399	+9%	+$2.36M	0.45%	50
2013 Q3	$24.4M	Buy	3,062,239 +815,353	+36%	+$6.55M	0.43%	52
2013 Q2	$17.3M	Buy	+2,246,886	New	+$17.5M	0.33%	80

Other funds holding PDLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Advisors Asset Management's PDLI Position: Q2 2018 in Review

Advisors Asset Management sold out of PDL BioPharma, Inc. (PDLI) in Q2 2018, closing a stake of 56,626 shares — an estimated $136K sold.

Advisors Asset Management first reported a position in PDLI in Q2 2013 and held it in 20 quarters. The position peaked at $45.8M in Q2 2014. 163 funds tracked by Wall St. Rank hold PDLI as of Q2 2018.

Advisors Asset Management reported no remaining PDL BioPharma, Inc. position as of Q2 2018 after selling out during the quarter.
Advisors Asset Management sold 56,626 PDL BioPharma, Inc. shares in Q2 2018, an estimated $136K.
Advisors Asset Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 20 quarters.
Advisors Asset Management's PDL BioPharma, Inc. position peaked at $45.8M in Q2 2014.
163 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2018.

Based on Advisors Asset Management's 13F filing for Q2 2018, filed 15 Aug 2018.